Screener / SEC EDGAR /CIK 0001377121 /10-K filed Feb 25, 2026, compared with Feb 21, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Protagonist Therapeutics, Inc PTGX

Compare with peers Embed
Earnings releases

Latest results release: Nov 5, 2026

8-K item 2.02, exhibit 99

What PTGX's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 5, 2026 · EX-99.1

Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate

Open on SEC

Exhibit 99.1 Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to Protagonist

Comprehensive Phase 2b Program with PN-881, an Oral IL-17 Antagonist for Psoriasis, Planned to Initiate in Early Q1 2027

Cash, Cash Equivalents and Marketable Securities of $834.6 Million as of September 30, 2026 NEWARK, Calif., November5, 2026 – Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“The third quarter was a defining period for Protagonist, with FDA approval of MIMRYLO, our second approval this year for a first-in-class peptide drug, and the continued strong commercial launch of ICOTYDE under our collaboration with Johnson & Johnson,” said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist Therapeutics. “MIMRYLO reflects years of disciplined scientific dedication and clinical execution, and together with ICOTYDE, provides immensely important validation both of our innovative expertise in peptide therapeutics and of the successful pharma-biotech partnership model we have built around these two approved drugs. The partnerships are fueling an accelerating revenue engine, which provides the flexibility to fund the next generation of wholly owned programs emerging from our platform, and to return meaningful capital to shareholders through a share repurchase program.”

MIMRYLO™(rusfertide): Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera

On August 28, Protagonist announced that its partner Takeda received U.S. Food and Drug Administration (FDA) approval of MIMRYLO for the treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO is the first and only hepcidin mimetic peptide therapy approved for this indication. On September 30, 2026, MIMRYLO was also approved in the United Arab Emirates. Protagonist discovered MIMRYLO and had primary responsibility for its clinical development · through its New Drug Application (“NDA”) filing in December 2025. ──────────────────────────────────────────────────────────────────────────────

The FDA approval of MIMRYLO triggered $275 million in payments to · Protagonist, consisting of a $200 million opt-out payment and a $75 million approval milestone.

Following Protagonist’s April 2026 opt-out election, Takeda holds exclusive worldwide development and commercialization rights to MIMRYLO. Protagonist is eligible to receive tiered royalties · ranging from 14% to 29% on worldwide net sales, corresponding to an approximately 21% weighted-average royalty rate at $1.5 billion in annual net sales. Protagonist is eligible for up to an additional $875 million in potential future milestone payments.

During the third quarter, ICOTYDE received regulatory approvals in China, Japan and the European Union for the treatment of psoriasis, · following U.S. FDA approval in March 2026. ICOTYDE is the first and only targeted oral peptide designed to precisely block the IL-23 receptor.

The third quarter of 2026 represents ICOTYDE’s second full quarter of U.S. commercial sales. Under the collaboration with Johnson & Johnson, Protagonist receives tiered royalties ranging from 6% to 10% on · global net sales, with an approximate 7.25% weighted-average royalty rate at $4 billion in annual net sales and a 10% tier applying to incremental annual sales above $4 billion. Protagonist is eligible for up to an additional $580 million in potential future milestone payments.

In September and October 2026, Johnson & Johnson presented two-year Phase 3 results from the ICONIC-TOTAL and ICONIC-LEAD · studies. The results demonstrated sustained responses through Week 112 and a continued favorable safety profile in adults and adolescents with plaque psoriasis, including patients with disease affecting high-impact and difficult-to-treat areas.

ICOTYDE is also in development for additional immune-mediated diseases, · including psoriatic arthritis, ulcerative colitis and Crohn’s disease.

PN-881 (oral IL-17 antagonist peptide for immune-mediated disease): The Phase 1 study of PN-881 has been completed. PN-881 achieved 24-hour trough concentrations several-fold above prospectively targeted IC90 values for IL-17AA, IL-17FF and · IL-17AA+FF with once-daily oral dosing and was generally well tolerated, with no serious adverse events. Protagonist plans to initiate a comprehensive Phase 2b dose range-finding study in patients with plaque psoriasis in early Q1 2027. Phase 1 data are expected to be presented at a future medical meeting.

PN-477 (triple GLP-1/GIP/GCG agonist peptide for obesity): In the subcutaneously administered PN-477sc Phase 1 SAD study we observed positive dose-related pharmacokinetic, pharmacodynamic and · clinical activity. Based on these highly encouraging findings, the Company has made a strategic decision to prioritize the orally administered PN-477o clinical development program. Initiation of a Phase 1 study of oral PN-477o is anticipated in the first half of 2027.

PN-458o (dual GLP-1/GIP agonist peptide for obesity): IND-enabling · studies are ongoing, with Phase 1 initiation anticipated in the second half of 2027.

PN-8047 (oral small molecule hepcidin functional mimetic for PV): · IND-enabling studies are ongoing, with Phase 1 initiation anticipated in Q1 2027.

Discovery: The Company continues to advance high-priority discovery · programs for oral peptides, including an oral IL-4Rα antagonist and amylin-based mono- and poly-agonists.

On September 8, Protagonist announced that its Board of Directors authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock. The Company intends to fund repurchases from its cash, cash equivalents · and marketable securities, as well as royalties and other payments received under its collaboration arrangements with Takeda related to MIMRYLO and Johnson & Johnson related to ICOTYDE. The timing and amount of any repurchases will depend on market conditions, alternative capital deployment opportunities and other factors.

Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents · and marketable securities as of September 30, 2026, were $834.6 million as compared to $646.0 million as of December 31, 2025.

License and Collaboration Revenue: License and collaboration revenue was $274.4 million for the third quarter of 2026. This revenue was primarily driven by the proportional recognition of $266.6 million related to the $275.0 million earned from Takeda during · the quarter. These payments, which were received in cash in October 2026, consisted of a further $200.0 million opt-out fee and a separate $75.0 million milestone triggered by the FDA approval of MIMRYLO. The remaining $7.8 million was derived from ongoing development services provided by us under the Takeda Collaboration Agreement, and other revenues.

License and collaboration revenue was $544.3 million for the nine months ended September 30, 2026. This cumulative revenue consisted primarily of $460.5 million related to total proportional revenue recognized from Takeda during those nine months. Additionally, the · nine-month revenue includes $33.8 million derived from ongoing development services provided by us under the Takeda Collaboration Agreement, a $50.0 million milestone earned from Johnson & Johnson in Q1 2026 upon FDA approval of ICOTYDE, and other revenues.

License and collaboration revenue of $4.7 million for the third quarter of 2025 was comprised of development services we provided under the Takeda collaboration agreement. License and collaboration revenue of $38.6 million for the nine months ended September 30, 2025, was comprised of (i) proportional recognition of a $25 million milestone earned from Takeda in Q1 2025, and (ii) development services we provided during the period.

Research and Development ("R&D") Expense: The increases in R&D expense from the prior year periods were primarily due to our clinical development and pre-clinical discovery programs, partially offset by decreases in rusfertide expenses related to the Phase 3 VERIFY clinical trial. We expect our R&D expenses to increase for the remainder of the year as compared to the prior quarters in 2026. The increase is expected to be driven primarily by the advancement of PN-881 into a comprehensive Phase 2 psoriasis program, planned investments in clinical manufacturing and CMC activities, including at-risk expenditures to ensure readiness for other programs as they advance into clinical development (PN-477o, PN-458, PN-8047), additional pre-clinical discovery programs, as well as an increase · in headcount and stock-based compensation expense. ──────────────────────────────────────────────────────────────────────────────

General and Administrative ("G&A") Expense: The increases in G&A expense from the prior year periods were primarily due to increases in stock-based compensation and other · personnel-related expenses. ──────────────────────────────────────────────────────────────────────────────

Net Income (Loss): Net income was $220.0 million, or $3.32 per basic share and $3.07 per diluted share, for the third quarter of 2026 as compared to net loss of $39.3 million, or $0.62 per basic and · diluted share, for the third quarter of 2025. Net income was $386.6 million, or $5.88 per basic share and $5.43 per diluted share, for the nine months ended September 30, 2026, as compared to net loss of $85.8 million, or $1.35 per basic and diluted share, for the nine months ended September 30, 2025.

Protagonist Therapeutics is a biopharmaceutical company built on a proprietary peptide technology platform that has now produced two FDA-approved, first-in- class medicines, generating royalties and milestones from global commercial partnerships with Johnson and Johnson and Takeda Pharmaceutical Company Limited. ICOTYDE® (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 (IL-23) receptor. ICOTYDE was launched in the U.S. in March 2026 for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further clinical and regulatory development and commercialization. Protagonist also discovered and led research and development through Phase 3 for MIMRYLO (rusfertide), a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceutical Company Limited for worldwide commercialization. MIMRYLO is approved in the U.S. for the treatment of erythrocytosis in adults with PV. The Company also has a number of clinical and preclinical programs based on clinically and commercially validated targets and addressing unmet medical needs, including an oral IL-17 antagonist peptide, anti-obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin discovery programs.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website athttps://www.protagonist-inc.com.

Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the company's expectations related to future royalty and milestone payments pursuant to the Company's collaboration arrangements, the timing and results of our clinical development programs, and the level of our future development expenses. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release. Investor Relations Contact

(1) Amount includes non-cash stock-based compensation expense. Stock-based Compensation

Full text with the tables
                                                                    Exhibit 99.1
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate 
                                     Update                                     
                                                                                
  MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in  
 Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to  
                                  Protagonist                                   
                                                                                
    Comprehensive Phase 2b Program with PN-881, an Oral IL-17 Antagonist for    
                Psoriasis, Planned to Initiate in Early Q1 2027                 
                                                                                
       $300 Million Share Repurchase Program Announced in September 2026        
                                                                                
    Cash, Cash Equivalents and Marketable Securities of $834.6 Million as of    
                               September 30, 2026                               
NEWARK, Calif., November5, 2026 – Protagonist Therapeutics (Nasdaq: PTGX)
(“Protagonist”
or “the Company”) today reported financial results for the third quarter ended
September 30, 2026, and provided a corporate
update.

“The third quarter was a defining period for Protagonist, with
FDA approval of MIMRYLO, our second approval this year for a first-in-class
peptide drug, and the continued strong commercial launch of
ICOTYDE under our collaboration with Johnson & Johnson,” said Dinesh V. Patel,
PhD, President and Chief Executive
Officer of Protagonist Therapeutics. “MIMRYLO reflects years of disciplined
scientific dedication and clinical execution, and together
with ICOTYDE, provides immensely important validation both of our innovative
expertise in peptide therapeutics and of the successful pharma-biotech
partnership model we have built around these two approved drugs. The
partnerships are fueling an accelerating revenue engine, which provides
the flexibility to fund the next generation of wholly owned programs emerging
from our platform, and to return meaningful capital to shareholders
through a share repurchase program.”

Third Quarter 2026 Recent Developments and Upcoming Milestones

MIMRYLO™(rusfertide): Subcutaneous Injectable Hepcidin Mimetic for Polycythemia
Vera
                                                                                
     On August 28,                                                              
     Protagonist announced that its partner Takeda received U.S. Food and Drug  
     Administration                                                             
     (FDA) approval of MIMRYLO for the treatment of erythrocytosis in adults    
     with polycythemia                                                          
     vera (PV). MIMRYLO is the first and only hepcidin mimetic peptide therapy  
     approved for this                                                          
     indication. On September 30, 2026, MIMRYLO was also approved in the        
     United Arab Emirates.                                                      
     Protagonist discovered MIMRYLO and had primary responsibility for its      
     clinical development                                                       
  ·  through its New Drug Application (“NDA”) filing in December 2025.          
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
     The FDA approval of MIMRYLO triggered $275 million in payments to          
  ·  Protagonist, consisting of a $200 million opt-out payment and a            
     $75 million approval milestone.                                            
                                                                                
                                                                                
     Following Protagonist’s April 2026 opt-out election, Takeda holds          
     exclusive worldwide development and commercialization                      
     rights to MIMRYLO. Protagonist is eligible to receive tiered royalties     
  ·  ranging from 14% to 29% on worldwide net sales, corresponding to           
     an approximately 21% weighted-average royalty rate at $1.5 billion in      
     annual net sales. Protagonist is eligible for up to an additional          
     $875 million in potential future milestone payments.                       
                                                                                
                                                                                
     On October 13,                                                             
     2026, results from the pivotal Phase 3 VERIFY study were published in the  
     Journal of Clinical                                                        
  ·  Oncology. The article is available here.                                   
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
ICOTYDE®(Icotrokinra): Oral IL-23 Receptor Antagonist
                                                                                
     During the third quarter, ICOTYDE received regulatory approvals in China,  
     Japan and the European Union for the treatment of psoriasis,               
  ·  following U.S. FDA approval in March 2026. ICOTYDE is the first and only   
     targeted oral peptide designed to precisely block the IL-23                
     receptor.                                                                  
                                                                                
                                                                                
     On October 14,                                                             
     2026, results from the Phase 2 ANTHEM-UC study were published in the New   
     England Journal                                                            
  ·  of Medicine. The article is available here.                                
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
     The third quarter of 2026 represents ICOTYDE’s second full quarter of      
     U.S. commercial sales. Under the collaboration with Johnson &              
     Johnson, Protagonist receives tiered royalties ranging from 6% to 10% on   
  ·  global net sales, with an approximate 7.25% weighted-average               
     royalty rate at $4 billion in annual net sales and a 10% tier applying to  
     incremental annual sales above $4 billion. Protagonist is eligible         
     for up to an additional $580 million in potential future milestone         
     payments.                                                                  
                                                                                
                                                                                
     In September and October 2026, Johnson & Johnson presented two-year Phase  
     3 results from the ICONIC-TOTAL and ICONIC-LEAD                            
  ·  studies. The results demonstrated sustained responses through Week 112     
     and a continued favorable safety profile in adults and adolescents         
     with plaque psoriasis, including patients with disease affecting           
     high-impact and difficult-to-treat areas.                                  
                                                                                
                                                                                
     ICOTYDE is also in development for additional immune-mediated diseases,    
  ·  including psoriatic arthritis, ulcerative colitis and Crohn’s              
     disease.                                                                   
                                                                                
Wholly-Owned Clinical and Discovery Programs
                                                                                
     PN-881 (oral IL-17 antagonist peptide for immune-mediated disease): The    
     Phase 1 study of PN-881 has been completed. PN-881                         
     achieved 24-hour trough concentrations several-fold above prospectively    
     targeted IC90 values for IL-17AA, IL-17FF and                              
  ·  IL-17AA+FF with once-daily oral dosing and was generally well tolerated,   
     with no serious adverse events. Protagonist plans to initiate              
     a comprehensive Phase 2b dose range-finding study in patients with plaque  
     psoriasis in early Q1 2027. Phase 1 data are expected to be                
     presented at a future medical meeting.                                     
                                                                                
                                                                                
     PN-477 (triple GLP-1/GIP/GCG agonist peptide for obesity): In the          
     subcutaneously administered PN-477sc Phase 1 SAD study we                  
     observed positive dose-related pharmacokinetic, pharmacodynamic and        
  ·  clinical activity. Based on these highly encouraging findings, the         
     Company has made a strategic decision to prioritize the orally             
     administered PN-477o clinical development program. Initiation of a Phase   
     1 study of oral PN-477o is anticipated in the first half of 2027.          
                                                                                
                                                                                
     PN-458o (dual GLP-1/GIP agonist peptide for obesity): IND-enabling         
  ·  studies are ongoing, with Phase 1 initiation anticipated                   
     in the second half of 2027.                                                
                                                                                
                                                                                
     PN-8047 (oral small molecule hepcidin functional mimetic for PV):          
  ·  IND-enabling studies are ongoing, with Phase 1 initiation                  
     anticipated in Q1 2027.                                                    
                                                                                
                                                                                
     Discovery: The Company continues to advance high-priority discovery        
  ·  programs for oral peptides, including an oral IL-4Rα                       
     antagonist and amylin-based mono- and poly-agonists.                       
                                                                                
Share Repurchase Program
                                                                                
     On September 8, Protagonist announced that its Board of Directors          
     authorized a share repurchase program under which the Company              
     may repurchase up to $300 million of its outstanding common stock. The     
     Company intends to fund repurchases from its cash, cash equivalents        
  ·  and marketable securities, as well as royalties and other payments         
     received under its collaboration arrangements with Takeda related to       
     MIMRYLO and Johnson & Johnson related to ICOTYDE. The timing and amount    
     of any repurchases will depend on market conditions,                       
     alternative capital deployment opportunities and other factors.            
                                                                                
Third Quarter 2026 Financial Results
                                                                                
     Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents   
  ·  and marketable securities as of September 30,                              
     2026, were $834.6 million as compared to $646.0 million as of December     
     31, 2025.                                                                  
                                                                                
                                                                                
  (in                                                                           
  thou…                                                                         
  exce…    Three                              Nine                              
  per      Mont…                              Months                            
  share    Ended  Septe…                      Ended   Sept…                     
  amou…    2026      30,    2025              2026      30,    2025             
 ────────────────────────────────────────────────────────────────────────────── 
  Lice…                                                                         
  and      $      274,4…    $     4,712       $       544,…    $     38,579     
  coll…                                                                         
  reve…                                                                         
  Rese…                                                                         
  and      $      41,274    $     40,0…       $       130,…    $     112,9…     
  deve…                                                                         
  expe…                                                                         
  Gene…                                                                         
  and      $      13,704    $     11,1…       $       39,6…    $     33,419     
  admi…                                                                         
  expe…                                                                         
  Inco…                                                                         
  tax      $       6,556    $        --       $       7,319    $        172     
  expe…                                                                         
  Net                                                                           
  inco…    $      220,0…    $     (39,…  )    $       386,…    $     (85,7…  )  
  (los…                                                                         
  Basic                                                                         
  earn…                                                                         
  (los…    $        3.32    $     (0.62  )    $        5.88    $      (1.35  )  
  per                                                                           
  share                                                                         
  Dilu…                                                                         
  earn…                                                                         
  (los…    $        3.07    $     (0.62  )    $        5.43    $      (1.35  )  
  per                                                                           
  share                                                                         
                                                                                
                                                                                
     License and Collaboration Revenue: License and collaboration revenue was   
     $274.4 million for the third quarter of 2026. This                         
     revenue was primarily driven by the proportional recognition of $266.6     
     million related to the $275.0 million earned from Takeda during            
  ·  the quarter. These payments, which were received in cash in October 2026,  
     consisted of a further $200.0 million opt-out fee and a                    
     separate $75.0 million milestone triggered by the FDA approval of          
     MIMRYLO. The remaining $7.8 million was derived from ongoing development   
     services provided by us under the Takeda Collaboration Agreement, and      
     other revenues.                                                            
                                                                                
                                                                                
     License and collaboration revenue was $544.3 million for the nine months   
     ended September 30, 2026. This cumulative revenue consisted                
     primarily of $460.5 million related to total proportional revenue          
     recognized from Takeda during those nine months. Additionally, the         
  ·  nine-month                                                                 
     revenue includes $33.8 million derived from ongoing development services   
     provided by us under the Takeda Collaboration Agreement, a $50.0           
     million milestone earned from Johnson & Johnson in Q1 2026 upon FDA        
     approval of ICOTYDE, and other revenues.                                   
                                                                                
License and collaboration revenue of $4.7 million for the
third quarter of 2025 was comprised of development services we provided under
the Takeda collaboration agreement. License and collaboration
revenue of $38.6 million for the nine months ended September 30, 2025, was
comprised of (i) proportional recognition of a $25
million milestone earned from Takeda in Q1 2025, and (ii) development services
we provided during the period.
                                                                                
     Research and Development ("R&D") Expense: The increases in R&D expense     
     from the prior year periods were primarily                                 
     due to our clinical development and pre-clinical discovery programs,       
     partially offset by decreases in rusfertide expenses related to the        
     Phase 3 VERIFY clinical trial. We expect our R&D expenses to increase for  
     the remainder of the year as compared to the prior quarters                
     in 2026. The increase is expected to be driven primarily by the            
     advancement of PN-881 into a comprehensive Phase 2 psoriasis program,      
     planned investments in clinical manufacturing and CMC activities,          
     including at-risk expenditures to ensure readiness for other programs      
     as they advance into clinical development (PN-477o, PN-458, PN-8047),      
     additional pre-clinical discovery programs, as well as an increase         
  ·  in headcount and stock-based compensation expense.                         
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
     General and Administrative ("G&A") Expense: The increases in G&A expense   
     from the prior year periods were                                           
     primarily due to increases in stock-based compensation and other           
  ·  personnel-related expenses.                                                
 ────────────────────────────────────────────────────────────────────────────── 
                                                                                
                                                                                
     Net Income (Loss): Net income was $220.0 million, or $3.32 per basic       
     share and $3.07 per diluted share, for the third quarter                   
     of 2026 as compared to net loss of $39.3 million, or $0.62 per basic and   
  ·  diluted share, for the third quarter of 2025. Net income was               
     $386.6 million, or $5.88 per basic share and $5.43 per diluted share, for  
     the nine months ended September 30, 2026, as compared to                   
     net loss of $85.8 million, or $1.35 per basic and diluted share, for the   
     nine months ended September 30, 2025.                                      
                                                                                
About Protagonist

Protagonist Therapeutics is a biopharmaceutical company built on a proprietary
peptide technology platform that has now produced two FDA-approved, first-in-
class medicines, generating royalties and milestones from global commercial
partnerships with Johnson and Johnson and Takeda Pharmaceutical Company Limited.
ICOTYDE® (icotrokinra), licensed
to Johnson & Johnson company Janssen Biotech, Inc., is the first and only
targeted oral peptide that precisely blocks the
Interleukin-23 (IL-23) receptor. ICOTYDE was launched in the U.S. in March 2026
for the treatment of moderate-to-severe plaque psoriasis
in adults and pediatric patients 12 years of age or older and is in Phase 3
development for psoriatic arthritis, ulcerative colitis and
Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson &
Johnson scientists, with Protagonist having primary
responsibility for the development of ICOTYDE through Phase 1, and Johnson &
Johnson assuming responsibility for further clinical
and regulatory development and commercialization. Protagonist also discovered
and led research and development through Phase 3 for MIMRYLO
(rusfertide), a first-in-class hepcidin mimetic peptide licensed to Takeda
Pharmaceutical Company Limited for worldwide commercialization.
MIMRYLO is approved in the U.S. for the treatment of erythrocytosis in adults
with PV. The Company also has a number of clinical and preclinical
programs based on clinically and commercially validated targets and addressing
unmet medical needs, including an oral IL-17 antagonist
peptide, anti-obesity dual and triple agonists, an oral hepcidin functional
mimetic, and the recently announced IL-4 and amylin discovery
programs.

More information on Protagonist, its pipeline drug candidates, and clinical
studies can be found on the Company's website athttps://www.protagonist-inc.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe 
harbor provisions of the Private Securities Litigation Reform Act of 1995.      
Forward-looking statements include statements regarding the company's           
expectations related to future royalty and milestone payments pursuant to the   
Company's collaboration arrangements, the timing and results of our clinical    
development programs, and the level of our future development expenses. In some 
cases, you can identify these statements by forward-looking words such as       
"anticipate," "believe," "may," "will," "expect," or the negative or plural of  
these words or similar expressions. Forward-looking statements are not          
guarantees of future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from those           
anticipated, including, but not limited to, our ability to develop and          
commercialize our product candidates, our ability to earn milestone payments    
under our collaboration agreements with Janssen and Takeda, our ability to use  
and expand our programs to build a pipeline of product candidates, our ability  
to obtain and maintain regulatory approval of our product candidates, our       
ability to operate in a competitive industry and compete successfully against   
competitors that have greater resources than we do, and our ability to obtain   
and adequately protect intellectual property rights for our product candidates. 
Additional information concerning these and other risk factors affecting our    
business can be found in our periodic filings with the Securities and Exchange  
Commission, including under the heading "Risk Factors" contained in our most    
recently filed periodic reports on Form 10-K and Form 10-Q filed with the       
Securities and Exchange Commission. Any forward-looking statements that we make 
in this press release speak only as of the date of this press release. We assume
no obligation to update our forward-looking statements, whether as a result of  
new information, future events, or otherwise, after the date of this press      
release.                                                                        
Investor Relations Contact

Corey Davis, Ph.D.

LifeSci Advisors

[email protected]

+1 212 915 2577

Media Relations Contact

Virginia Amann

ENTENTE Network of Companies

[email protected]

+1 833 500 0061 ext 1
                         PROTAGONIST THERAPEUTICS, INC.                         
                                                                                
                     Consolidated Statements of Operations                      
                                                                                
             (Amounts in thousands except share and per share data)             
                                                                                
          Three                               Nine                              
          Mont…                               Mont…                             
          Ended  Sept…                        Ended  Sep…                       
          2026     30,       2025             2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Lic…                                                                          
  and     $      274,…       $     4,7…       $      544…       $     38,5…     
  col…                                                                          
  rev…                                                                          
  Ope…                                                                          
  exp…                                                                          
  Cost                                                                          
  of             1,100                -              1,1…                 -     
  rev…                                                                          
  Res…                                                                          
  and            41,2…             40,…              130…             112,…     
  dev…                                                                          
  (1)                                                                           
  Gen…                                                                          
  and            13,7…             11,…              39,…             33,4…     
  adm…                                                                          
  (1)                                                                           
  Tot…                                                                          
  ope…           56,0…             51,…              170…             146,…     
  exp…                                                                          
  Inc…                                                                          
  (lo…           218,…             (46…  )           373…             (107…  )  
  from                                                                          
  ope…                                                                          
  Int…           8,253             7,0…              20,…             22,0…     
  inc…                                                                          
  Oth…                                                                          
  (ex…             (14  )            33               (42  )            151     
  inc…                                                                          
  net                                                                           
  Inc…                                                                          
  (lo…                                                                          
  bef…           226,…             (39…  )           393…             (85,…  )  
  inc…                                                                          
  tax                                                                           
  exp…                                                                          
  Inc…                                                                          
  tax            6,556                -              7,3…               172     
  exp…                                                                          
  Net                                                                           
  inc…    $      220,…       $     (39…  )    $      386…       $     (85,…  )  
  (lo…                                                                          
  Net                                                                           
  inc…                                                                          
  (lo…    $       3.32       $     (0.…  )    $      5.88       $     (1.35  )  
  per                                                                           
  sha…                                                                          
  bas…                                                                          
  Net                                                                           
  inc…                                                                          
  (lo…    $       3.07       $     (0.…  )    $      5.43       $     (1.35  )  
  per                                                                           
  sha…                                                                          
  dil…                                                                          
  Wei…                                                                          
  sha…                                                                          
  used                                                                          
  to                                                                            
  com…                                                                          
  net            66,3…             63,…              65,…             63,4…     
  inc…                                                                          
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  bas…                                                                          
  Wei…                                                                          
  sha…                                                                          
  used                                                                          
  to                                                                            
  com…                                                                          
  net            71,7…             63,…              71,…             63,4…     
  inc…                                                                          
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  dil…                                                                          
                                                                                
(1) Amount includes non-cash
stock-based compensation expense.
                            Stock-based Compensation                            
                                                                                
                                 (In thousands)                                 
                                                                                
            Three                              Nine                             
            Months                             Months                           
            Ended    Septe…                    Ended    Septe…                  
            2026        30,    2025            2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Resea…                                                                        
  and       $         7,728    $      6,019    $        23,056    $     20,301  
  devel…                                                                        
  Gener…                                                                        
  and                 6,635           4,540             19,864          14,972  
  admin…                                                                        
  Total                                                                         
  stock…    $        14,363    $     10,559    $        42,920    $     35,273  
  compe…                                                                        
  expen…                                                                        
                                                                                
                         PROTAGONIST THERAPEUTICS, INC.                         
                                                                                
                    Selected Consolidated Balance Sheet Data                    
                                                                                
                                 (In thousands)                                 
                                                                                
                               2026  September 30,       2025  December 31,     
 ────────────────────────────────────────────────────────────────────────────── 
  Cash, cash equivalents                                                        
  and marketable               $           834,621       $          646,002     
  securities                                                                    
  Working capital                        1,045,595                  532,133     
  Total assets                           1,146,551                  668,188     
  Deferred revenue                          16,311                    9,550     
  Accumulated deficit                      (84,024  )              (470,671  )  
  Total stockholders'                    1,084,910                  614,707     
  equity                                                                        
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PTGX/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.